Sophie Beauchemin

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Allergan, Inc., Ocera Therapeutics, Inc., Tranzyme Pharma Inc.. Active years: 2004-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sophie Beauchemin. Retrieved from https://idiyas.com/inventor/sophie-beauchemin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 13(Granted Patents)

Location History:

Québec, CA (2013)
Sherbrooke, CA (2004 - 2018)

Company Filing History:

Ocera Therapeutics, Inc.

Years Active: 2004-2018

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10040751 - Intermediates for macrocyclic compounds (2018-08-07),

2. 9371297 - Macrocyclic ghrelin receptor modulators and methods of using the same (2016-06-21),

3. 9181298 - Intermediates for macrocyclic compounds (2015-11-10),

4. 8497242 - Processes for intermediates for macrocyclic compounds (2013-07-30),

5. 8440851 - Spatially-defined macrocyclic compounds useful for drug discovery (2013-05-14),

6. 7935825 - Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain (2011-05-03),

7. 7214678 - Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain (2007-05-08),

8. 7098223 - Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain (2006-08-29),

9. 6825221 - Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain (2004-11-30),

Title: Sophie Beauchemin: Innovator in Macrocyclic Compounds

Introduction

Sophie Beauchemin is a prominent inventor based in Sherbrooke, Canada. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of macrocyclic compounds. With a total of nine patents to her name, her work has the potential to impact various medical conditions.

Latest Patents

One of her latest patents is focused on intermediates for macrocyclic compounds. This invention is directed towards novel macrocyclic compounds and their pharmaceutically acceptable salts, hydrates, or solvates. These compounds are designed to act as antagonists of the motilin receptor, which can be useful in treating disorders associated with motility dysfunction. Another significant patent involves macrocyclic ghrelin receptor modulators. This invention provides novel conformationally-defined macrocyclic compounds that function as selective modulators of the ghrelin receptor. These compounds are intended for use as agonists of the ghrelin receptor and can serve as medicaments for a range of medical conditions, including metabolic and endocrine disorders, gastrointestinal disorders, and obesity-related issues.

Career Highlights

Throughout her career, Sophie has worked with notable companies such as Allergan, Inc. and Ocera Therapeutics, Inc. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical development and innovation.

Collaborations

Sophie has collaborated with esteemed colleagues, including Kamel Benakli and Hamid R. Hoveyda. These partnerships have contributed to her success in the field and have fostered a collaborative environment for innovation.

Conclusion

Sophie Beauchemin is a trailblazer in the realm of macrocyclic compounds, with a strong portfolio of patents that showcase her innovative spirit. Her work continues to pave the way for advancements in medical treatments and pharmaceutical applications.

Profile summary based on public USPTO records.